Fardis Shahrivar, MD
Pediatrics · San Jose
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- 4
- 3 carriers
- Office
- 1
On the public record
- Medicare does not list them as allowed to order and refer
Offices
1 location
Plans that list them
4 plans · 3 carriers
A missing listing does not mean out of network. Directories change, and a listing does not cover every office. Call Dr. Shahrivar’s office at (408) 729-4473 to confirm they take your plan. Ask about the office you use, its medical group, referrals and appointments.
4 of 4 plans
| Anthem Full Dual Advantage Aligned (HMO D-SNP) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Medicare Advantage (HMO-POS) | Anthem Blue Cross | Listed | Oct 3, 2026 |
| Anthem Prime (HMO-POS) | Anthem Blue Cross Partnership Plan | Listed | Oct 3, 2026 |
| Blue Shield Inspire (HMO) | Blue Shield of California | Listed | Aug 26, 2026 |
Medicaid work
$5,691 in 2024
Medicaid paid $5,691 for 1,375 billed services this clinician did in 2024, up to 132 people in a month for one service.
Medicaid and CHIP claims where this clinician did the service, fee-for-service and managed care together. Any month with fewer than 11 patients is hidden, so small Medicaid practices undercount.
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 274 | $2,714 |
| LIMITED VISUAL FIELD XM UNI/BI I&R | 38 | $1,381 |
| Pure tone audiometry (threshold); air only | 40 | $731 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 12 | $725 |
| Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use | 14 | $139 |
| Short return visit (20+ min) | 950 | $0 |
| Screening performed and negative | 47 | $0 |
| 2024 | 1,375 | 7 | 132 | $5,691 |
| 2023 | 3,172 | 13 | 134 | $42,514 |
| 2022 | 3,040 | 14 | 109 | $45,465 |
| 2021 | 2,474 | 15 | 130 | $45,581 |
| 2020 | 2,617 | 14 | 224 | $42,844 |
| 2019 | 2,140 | 9 | 93 | $36,161 |
| 2018 | 2,242 | 12 | 101 | $37,187 |
See the largest Medicaid services in earlier years
2023
| LIMITED VISUAL FIELD XM UNI/BI I&R | 433 | $15,622 |
| Pure tone audiometry (threshold); air only | 431 | $7,771 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 96 | $5,803 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 289 | $2,865 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, single dose | 63 | $2,520 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 42 | $1,881 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 33 | $1,595 |
| Short return visit (20+ min) | 1,127 | $1,563 |
| Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use | 122 | $1,208 |
| Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, 25 mcg/0.25 mL dosage, for intramuscular use | 29 | $720 |
| Poliovirus vaccine, inactivated (IPV), for subcutaneous or intramuscular use | 44 | $434 |
| Screening performed and negative | 450 | $406 |
2022
| LIMITED VISUAL FIELD XM UNI/BI I&R | 393 | $14,096 |
| Pure tone audiometry (threshold); air only | 401 | $7,171 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 98 | $5,864 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose | 125 | $4,960 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 363 | $3,604 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; second dose | 66 | $2,640 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 54 | $2,610 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose | 42 | $1,680 |
| Short return visit (20+ min) | 1,018 | $988 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 3 mcg/0.2 mL dosage, diluent reconstituted, tris-sucrose formulation; second dose | 14 | $560 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 13 | $536 |
| Screening performed and negative | 423 | $458 |
2021
| LIMITED VISUAL FIELD XM UNI/BI I&R | 407 | $14,714 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 148 | $8,947 |
| Pure tone audiometry (threshold); air only | 402 | $7,276 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 305 | $3,024 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 63 | $2,997 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; first dose | 62 | $2,430 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; second dose | 61 | $2,280 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 52 | $2,218 |
| Immunization administration by intramuscular injection of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) (coronavirus disease [COVID-19]) vaccine, mRNA-LNP, spike protein, preservative free, 30 mcg/0.3 mL dosage, diluent reconstituted; third dose | 25 | $1,000 |
| Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use | 29 | $288 |
| Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use | 14 | $129 |
| DIPHTH TETANUS TOX ACELL PERTUSSIS VACC<7 YR IM | 13 | $129 |
2020
| LIMITED VISUAL FIELD XM UNI/BI I&R | 431 | $14,859 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 137 | $8,100 |
| Pure tone audiometry (threshold); air only | 416 | $7,457 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 93 | $4,447 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 426 | $4,274 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; 18-39 years | 14 | $1,238 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 26 | $1,031 |
| Meningococcal recombinant lipoprotein vaccine, serogroup B (MenB-FHbp), 2 or 3 dose schedule, for intramuscular use | 91 | $883 |
| Human Papillomavirus vaccine types 6, 11, 16, 18, 31, 33, 45, 52, 58, nonavalent (9vHPV), 2 or 3 dose schedule, for intramuscular use | 28 | $268 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 16 | $159 |
| Meningococcal conjugate vaccine, serogroups A, C, W, Y, quadrivalent, diphtheria toxoid carrier (MenACWY-D) or CRM197 carrier (MenACWY-CRM), for intramuscular use | 13 | $129 |
| Short return visit (20+ min) | 645 | $0 |
2019
| LIMITED VISUAL FIELD XM UNI/BI I&R | 367 | $13,042 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 154 | $7,251 |
| Pure tone audiometry (threshold); air only | 359 | $6,497 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 80 | $4,352 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 61 | $2,350 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 227 | $2,182 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use | 39 | $367 |
| DIPHTH TETANUS TOX ACELL PERTUSSIS VACC<7 YR IM | 14 | $119 |
| Short return visit (20+ min) | 839 | $0 |
2018
| LIMITED VISUAL FIELD XM UNI/BI I&R | 377 | $13,297 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; late childhood (age 5 through 11 years) | 155 | $7,396 |
| Pure tone audiometry (threshold); air only | 313 | $5,597 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; adolescent (age 12 through 17 years) | 70 | $4,232 |
| Periodic comprehensive preventive medicine reevaluation and management of an individual including an age and gender appropriate history, examination, counseling/anticipatory guidance/risk factor reduction interventions, and the ordering of laboratory/diagnostic procedures, established patient; early childhood (age 1 through 4 years) | 85 | $3,421 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.5 mL dosage, for intramuscular use | 205 | $1,944 |
| Screening test, pure tone, air only | 54 | $650 |
| Influenza virus vaccine, quadrivalent (IIV4), split virus, preservative free, 0.25 mL dosage, for intramuscular use | 29 | $228 |
| Skin test; tuberculosis, intradermal | 48 | $174 |
| DIPHTH TETANUS TOX ACELL PERTUSSIS VACC<7 YR IM | 13 | $129 |
| Tetanus, diphtheria toxoids and acellular pertussis vaccine (Tdap), when administered to individuals 7 years or older, for intramuscular use | 12 | $119 |
| Short return visit (20+ min) | 881 | $0 |
Money from drug and device companies
$110 in 2022
| 2022 | 5 | 5 | None | $110 |
| 2021 | 2 | 2 | None | $58 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
A payment is not proof that care is biased.
| Sobi | Doptelet | $25 | 1 payment
|
| AstraZeneca Pharmaceuticals LP | Tagrisso | $23 | 1 payment
|
| Blue Earth Diagnostics | Axumin | $22 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $22 | 1 payment
|
| Takeda Pharmaceuticals U.S.A. | Ninlaro | $18 | 1 payment
|
See all 5 published payments
| Sobi | Meals · 2022-05-24 | Doptelet | $25 |
| AstraZeneca Pharmaceuticals LP | Meals · 2022-05-11 | Tagrisso | $23 |
| Merck Sharp & Dohme | Meals · 2022-04-27 | Keytruda | $22 |
| Takeda Pharmaceuticals U.S.A. | Meals · 2022-04-06 | Ninlaro | $18 |
| Blue Earth Diagnostics | Meals · 2022-03-16 | Axumin | $22 |
See earlier years (2021)
2021: $58
| Janssen Biotech | None | $35 | 1 payment
|
| Merck Sharp & Dohme | Keytruda | $23 | 1 payment
|
Professional record
- NPI
- 1689779746
- Licence
- CA AO49985
More record details
- Sole proprietor
- Yes
- Medicaid ID
- CA 00A499851
- Taxonomy
- Pediatrics (208000000X)
- Mailing address
- 200 Jose Figueres Ave, Suite 295, San Jose, CA, 95116
- NPI first listed
- 2006-09-14
- NPI last updated
- 2008-05-22
This is when the NPI record was last certified, not a medical board exam.